Biochemical screening for Down syndrome: patients' perception of risk
| Autor: | M.P O’Connell, S.W. Lindow, Stephen Holding, R. J. Morgan |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
Down syndrome Aneuploidy Chorionic Gonadotropin Predictive Value of Tests Pregnancy medicine Humans Invasive Procedure Gynecology medicine.diagnostic_test Estriol Obstetrics business.industry Triple test Obstetrics and Gynecology General Medicine medicine.disease Patient perceptions Amniocentesis Female alpha-Fetoproteins Down Syndrome Complication business |
| Zdroj: | International Journal of Gynecology & Obstetrics. 68:215-218 |
| ISSN: | 0020-7292 |
| DOI: | 10.1016/s0020-7292(99)00165-4 |
| Popis: | Objectives: To determine the utility of the triple test in routine clinical practice and in addition to the document, the acceptability of a cut-off of 1:250 for invasive testing. Design: Retrospective analysis of data from screening and invasive testing for Down syndrome over a 5-year period in Hull Maternity Hospital. Computer-based records were accessed and individual data drawn from case notes were analyzed. Results: 14 827 (78%) of all patients opted for the triple test. A positive result (1:250 or greater) was found in 586 (4%). Fifteen percent of this group refused further testing with amniocentesis. 0.08% requested amniocentesis despite a negative triple test result. Of the screened pregnancies the triple test and selective invasive testing identified nine out of 15 (60%) of Down syndrome cases. Conclusion: Sixty percent of Down syndrome pregnancies were identified with a 4% invasive testing rate. Fifteen percent of women who had a positive test did not agree with the cut-off of 1:250 and therefore declined invasive testing. Invasive procedure complication rates do not equate with patients’ perception of Down syndrome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text